Shots:

• Teva and Celltrion report the availability of Herzuma (trastuzumab-pkrb)- a biosimilar referencing Herceptin in the US. The biosimilar is designed to treat the same indications as to reference product relating to breast cancer and gastric cancer
• The drug will be available at WAC of $1-402.50 for a 150mg dosage and $3-927 for a 420mg dosage- representing a 10% discount on the WAC of Herceptin
• Herzuma (trastuzumab-pkrb) is a biosimilar referencing Herceptin- with no differences in safety- purity and potency. In Oct’2016- the companies signed an exclusive partnership to commercialize Herzuma in the US & Canada

Click here ­to­ read full press release/ article 

 Ref: Teva  | Image:  Celltrion